A

Amerisourcebergen Corp
F:ABG

Watchlist Manager
Amerisourcebergen Corp
F:ABG
Watchlist
Price: 295.05 EUR 1.04% Market Closed
Market Cap: 58.8B EUR

Intrinsic Value

The intrinsic value of one ABG stock under the Base Case scenario is 434.12 EUR. Compared to the current market price of 295.05 EUR, Amerisourcebergen Corp is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABG Intrinsic Value
434.12 EUR
Undervaluation 32%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation History
Amerisourcebergen Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about ABG?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is ABG valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Amerisourcebergen Corp.

Explain Valuation
Compare ABG to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

The ongoing litigation and regulatory scrutiny surrounding the opioid crisis pose material financial and reputational risks, potentially leading to hefty settlements and stricter distribution requirements that could compress margins.

Shrinking margins in the pharmaceutical wholesale industry, driven by aggressive pricing negotiations from large healthcare providers and rising competition from other distributors, may curb AmerisourceBergen’s profitability despite continued volume growth.

Any reduced dependence on wholesale distributors by major pharmacy chains, compounded by the threat of new digital entrants aiming to bypass traditional distribution channels, could cut into AmerisourceBergen’s core revenue streams.

Bull Theses

AmerisourceBergen’s deep-rooted partnerships, such as those with Walgreens Boots Alliance, grant the firm a scale advantage that helps lock in large distribution contracts and fortify its competitive position.

Strategic focus on specialty pharmaceuticals—particularly oncology and biosimilars—positions AmerisourceBergen to benefit from growing demand in complex therapies and advanced medications, supporting higher margins than traditional generics.

Investment in global reach through acquisitions and expansion into emerging markets bolsters the company’s ability to capture cross-border opportunities and further diversify its revenue base.

Show More Less
How do you feel about 0HF3?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Amerisourcebergen Corp

Current Assets 52.2B
Cash & Short-Term Investments 4.4B
Receivables 26.9B
Other Current Assets 21B
Non-Current Assets 24.4B
PP&E 2.5B
Intangibles 17.5B
Other Non-Current Assets 4.4B
Current Liabilities 57.8B
Accounts Payable 54.7B
Accrued Liabilities 3B
Other Current Liabilities 117.8m
Non-Current Liabilities 17.3B
Long-Term Debt 7.5B
Other Non-Current Liabilities 9.7B
Efficiency

Free Cash Flow Analysis
Amerisourcebergen Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Amerisourcebergen Corp

Revenue
321.3B USD
Cost of Revenue
-310B USD
Gross Profit
11.3B USD
Operating Expenses
-7.5B USD
Operating Income
3.7B USD
Other Expenses
-2.2B USD
Net Income
1.6B USD
Fundamental Scores

ABG Profitability Score
Profitability Due Diligence

Amerisourcebergen Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROE
Exceptional ROE
Positive 3Y Average ROIC
Positive ROIC
56/100
Profitability
Score

Amerisourcebergen Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

ABG Solvency Score
Solvency Due Diligence

Amerisourcebergen Corp's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Positive Net Debt
Long-Term Solvency
High Interest Coverage
51/100
Solvency
Score

Amerisourcebergen Corp's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABG Price Targets Summary
Amerisourcebergen Corp

Wall Street analysts forecast ABG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABG is 329.83 EUR with a low forecast of 237.83 EUR and a high forecast of 369.27 EUR.

Lowest
Price Target
237.83 EUR
19% Downside
Average
Price Target
329.83 EUR
12% Upside
Highest
Price Target
369.27 EUR
25% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 0HF3 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

0HF3 Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one ABG stock?

The intrinsic value of one ABG stock under the Base Case scenario is 434.12 EUR.

Is ABG stock undervalued or overvalued?

Compared to the current market price of 295.05 EUR, Amerisourcebergen Corp is Undervalued by 32%.

Back to Top